Craig Teveliet
Family Medicine · Hoquiam, WANPI 1366411365
Payments from drug & device makers
Across 481 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$1K
- Lilly USA, LLC$790
- Pfizer$763
- Novo Nordisk$716
- AbbVie$504
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,47099%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 74 | $1,339 |
| AstraZeneca | 51 | $1,036 |
| Lilly USA, LLC | 53 | $790 |
| Pfizer | 50 | $763 |
| Novo Nordisk | 40 | $716 |
| AbbVie(2 entities) | 30 | $504 |
| Boehringer Ingelheim | 22 | $421 |
| Novartis | 22 | $404 |
| Bayer | 20 | $390 |
| GSK | 17 | $322 |
| Johnson & Johnson | 15 | $284 |
| Sanofi-aventis U.S. LLC | 11 | $207 |
| Mylan Specialty L.p. | 7 | $124 |
| Kowa Pharmaceuticals America, Inc. | 6 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $110 |
| Exact Sciences | 4 | $100 |
| Amarin Pharma, Inc. | 6 | $97 |
| Biohaven Pharmaceuticals, Inc. | 5 | $96 |
| Astellas Pharma US Inc | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Dexcom, Inc. | 4 | $70 |
| Merck | 4 | $63 |
| Arbor Pharmaceuticals, Inc. | 4 | $53 |
| CMP Pharma, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $44 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Viatris Specialty LLC | 1 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Tanabe Pharma America, Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| Gilead | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$8,520 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 249 | $196,668 |
| MounjaroTirzepatide | 143 | $165,001 |
| JardianceEmpagliflozin | 155 | $151,150 |
| TrulicityDulaglutide | 90 | $89,613 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $69,378 |
| FarxigaDapagliflozin Propanediol | 61 | $65,959 |
| Tresiba Flextouch U-200Insulin Degludec | 68 | $59,958 |
| OzempicSemaglutide | 50 | $52,527 |
| MyrbetriqMirabegron | 74 | $48,372 |
| XareltoRivaroxaban | 42 | $45,027 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $31,091 |
| KerendiaFinerenone | 35 | $27,882 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 50 | $22,162 |
| TradjentaLinagliptin | 21 | $21,464 |
| Repatha SureclickEvolocumab | 38 | $20,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $790 | $254,614233 claims |
| PfizerEliquis, Premarin | $763 | $201,622263 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Spiriva Respimat | $421 | $195,982223 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $322 | $96,039132 claims |
| AstraZenecaFarxiga | $1,036 | $65,95961 claims |
| Novo NordiskOzempic, Rybelsus | $716 | $64,73364 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $48,37274 claims |
| Johnson & JohnsonXarelto | $284 | $45,02742 claims |
| BayerKerendia | $390 | $27,88235 claims |
| MerckJanuvia | $63 | $19,76320 claims |
| AbbVieVraylar | $504 | $16,00011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $44 | $3,61612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Hoquiam
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.